Skip to main content

Calling SMEs and consultants

One of the anticipated user groups for the ChEMBL data are for SMEs and 'sole trader' type consultants (i.e. very small consultancy businesses, one-person-bands, etc.). So, as a general question, what sort of access and query tools would be most useful for this type of user. We have contacts with quite a lot of large pharma, non-profits, universities and larger biotech, especially in Europe and the USA, but could do with more diverse contacts to make sure we align our services with a broader community.

I guess there are a number of obvious options for delivery.

  • Locally installable databases - what sort of technical environment would be wanted for this (Oracle, mySQL, ....)
  • Hosted web server access - what sort of queries would people want to do, how would they like the results?

    Where should our priorities lie?

    So, please, mail me (jpo (at) ebi.ac.uk) if you have some thoughts, or would consider yourself to be one of these types of users. Contact and input from developing economies is especially welcome.

  • Comments

    Popular posts from this blog

    RDKit, C++ and Jupyter Notebook

    Fancy playing with RDKit C++ API without needing to set up a C++ project and compile it? But wait... isn't C++ a compiled programming language? How this can be even possible?

    Thanks to Cling (CERN's C++ interpreter) and xeus-cling jupyter kernel is possible to use C++ as an intepreted language inside a jupyter notebook!

    We prepared a simple notebook showing few examples of RDKit functionalities and a docker image in case you want to run it.

    With the single requirement of docker being installed in your computer you'll be able to easily run the examples following the three steps below:
    docker pull eloyfelix/rdkit_jupyter_clingdocker run -d -p 9999:9999 eloyfelix/rdkit_jupyter_clingopen http://localhost:9999/notebooks/rdkit_cling.ipynb in a browser


    ChEMBL 25 and new web interface released

    We are pleased to announce the release of ChEMBL 25 and our new web interface. This version of the database, prepared on 10/12/2018 contains:

    2,335,417 compound records1,879,206 compounds (of which 1,870,461 have mol files)15,504,603 activities1,125,387 assays12,482 targets72,271 documents

    Data can be downloaded from the ChEMBL ftp site: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25

    Please see ChEMBL_25 release notes for full details of all changes in this release: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25/chembl_25_release_notes.txt


    DATA CHANGES SINCE THE LAST RELEASE

    # Deposited Data Sets:

    Kuster Lab Chemical Proteomics Drug Profiling (src_id = 48, Document ChEMBL_ID = CHEMBL3991601):
    Data have been included from the publication: The target landscape of clinical kinase drugs. Klaeger S, Heinzlmeir S and Wilhelm M et al (2017), Science, 358-6367 (https://doi.org/10.1126/science.aan4368)

    # In Vivo Assay Classification:

    A classification…

    FPSim2, a simple Python3 molecular similarity tool

    FPSim2 is a new tool for fast similarity search on big compound datasets (>100 million) being developed at ChEMBL. We started developing it as we needed a Python3 library able to run either in memory or out-of-core fast similarity searches on such dataset sizes.

    It's written in Python/Cython and features:
    A fast population count algorithm (builtin-popcnt-unrolled) from https://github.com/WojciechMula/sse-popcount using SIMD instructions.Bounds for sub-linear speed-ups from 10.1021/ci600358fA compressed file format with optimised read speed based in PyTables and BLOSCUse of multiple cores in a single search In memory and on disk search modesSimple and easy to use
    Source code is available on github and Conda packages are also available for either mac or linux. To install it type:

    conda install rdkit -c rdkitconda install fpsim2 -c efelix
    Try it with docker (much better performance than binder):

        docker pull eloyfelix/fpsim2    docker run -p 9999:9999 eloyfelix/fpsim2    open htt…

    2019 and ChEMBL – News, jobs and birthdays

    Happy New Year from the ChEMBL Group to all our users and collaborators. 
    Firstly, do you want a new challenge in 2019?  If so, we have a position for a bioinformatician in the ChEMBL Team to develop pipelines for identifying links between therapeutic targets, drugs and diseases.  You will be based in the ChEMBL team but also work in collaboration with the exciting Open Targets initiative.  More details can be found here(closing date 24thJanuary). 
    In case you missed it, we published a paper at the end of last on the latest developments of the ChEMBL database “ChEMBL: towards direct deposition of bioassay data”. You can read it here.  Highlights include bioactivity data from patents, human pharmacokinetic data from prescribing information, deposited data from neglected disease screening and data from the IMI funded K4DD project.  We have also added a lot of new annotations on the therapeutic targets and indications for clinical candidates and marketed drugs to ChEMBL.  Importantly we ha…

    ChEMBL_27 SARS-CoV-2 release

    The COVID-19 pandemic has resulted in an unprecedented effort across the global scientific community. Drug discovery groups are contributing in several ways, including the screening of compounds to identify those with potential anti-SARS-CoV-2 activity. When the compounds being assayed are marketed drugs or compounds in clinical development then this may identify potential repurposing opportunities (though there are many other factors to consider including safety and PK/PD considerations; see for example https://www.medrxiv.org/content/10.1101/2020.04.16.20068379v1.full.pdf+html). The results from such compound screening can also help inform and drive our understanding of the complex interplay between virus and host at different stages of infection.
    Several large-scale drug screening studies have now been described and made available as pre-prints or as peer-reviewed publications. The ChEMBL team has been following these developments with significant interest, and as a contribution t…